Eagle Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

·1 min read

Eagle Pharmaceuticals (NASDAQ:EGRX) Full Year 2022 Results

Key Financial Results

  • Revenue: US$316.6m (up 85% from FY 2021).

  • Net income: US$35.6m (up from US$8.63m loss in FY 2021).

  • Profit margin: 11% (up from net loss in FY 2021).

  • EPS: US$2.76 (up from US$0.66 loss in FY 2021).


All figures shown in the chart above are for the trailing 12 month (TTM) period

Eagle Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) exceeded analyst estimates by 75%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 13% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 3.4% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for Eagle Pharmaceuticals (1 is concerning!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here